Halozyme Therapeutics, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:HALO) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 2.2 B2.05 B2.22 B2.53 B2.67 B2.58 B Total liabilities 1.71 B1.72 B1.72 B2.48 B2.45 B2.43 B Total equity 482.27 M332.75 M503.92 M48.81 M219.64 M143.54 M Total liabilities & shareholders' equities 2.2 B2.05 B2.22 B2.53 B2.67 B2.58 B Total debt 1.51 B1.51 B1.51 B2.14 B2.14 B2.15 B Net debt 1.51 B1.51 B380.41 M2.01 B1.63 B1.98 B

News

4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be the Cure

Halozyme: The Market May Be Underpricing The Second Growth Wave (NASDAQ:HALO)

Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"

Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?

Tight Action In HALO Stock Sets Up Heavenly Gains

Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice

Zacks.com featured highlights Herbalife, Honda Motor, Marathon, Halozyme and Genworth

5 Value Stocks to Buy Right Now as Inflation Remains Sticky

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

5 Biotech Stocks Worth Adding to Your Portfolio Now